Skip to main content

Table 2 Correlation between VLDLR II expression and clinical features in 52 gastric cancer patients

From: Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to β-catenin in different cancers

Parameters Number VLDLR II fold P
Age at diagnosis    
≥ 60 years 26 1.34 ± 0.58 0.133
< 60 years 26 1.19 ± 0.55  
Gender    
Male 37 1.28 ± 0.58 0.709
Female 15 1.22 ± 0.55  
Body weight    
≥ 60 kg 17 1.14 ± 0.31 0.565
< 60 kg 35 1.33 ± 0.65  
TC    
> 5.20 mmol/L 11 1.11 ± 0.20 0.662
≤ 5.20 mmol/L 41 1.31 ± 0.62  
TG    
> 1.70 mmol/L 9 1.02 ± 0.23 0.204
≤ 1.70 mmol/L 43 1.32 ± 0.60  
Histological grade    
Well to moderately differentiated 30 1.19 ± 0.55 0.165
Poorly differentiated 22 1.37 ± 0.58  
Tumor size    
≥ 5 cm 25 1.40 ± 0.60 0.087
< 5 cm 27 1.14 ± 0.51  
Lymph node metastasis    
Negative 15 1.02 ± 0.51 0.013*
Positive 37 1.35 ± 0.56  
Distant metastasis    
Negative 41 1.13 ± 0.41 0.004*
Positive 11 1.78 ± 0.77  
TNM stage    
Stage I-II 22 1.08 ± 0.46 0.011*
Stage III-IV 30 1.40 ± 0.60  
  1. Folds (VLDLR II protein in tumor/in normal) in mean ± SD, VLDLR II measured by Western blot. TC, total cholesterol (normal range: ≤ 5.20 mmol/L); TG, triglycerides (normal range: ≤ 1.70 mmol/L). Statistical analyses were performed by Mann-Whitney test.
  2. * P < 0.05 is considered significant